 |
 |
 |
 |
 |
 |
 |
Oncology Trials
The Oncology Research Program, in partnership with local oncologists, offers patients access to leading-edge clinical trials sponsored by the National Cancer Institute's Cooperative Group Program or by pharmaceutical companies. These clinical trials study investigational drugs, new combinations of standard treatments for cancer, or cancer prevention in high risk patients.
For more information, please contact Suburban Hospital Oncology Research:
Barbara Squiller |
Melissa Hyman |
For information about clinical trials, visit the National Cancer Institute.
BREAST |
|
N0733 |
Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 in Patients with HER2 Positive Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane. |
BOLERO2 |
A Randomized Double-Blind, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrozole or Anastrozole. |
TAILORx |
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial. |
BETH |
Bevacizumab with Trastuzumab Adjuvant Therapy in HER2+ Breast Cancer. A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab. |
NSABP B-42 |
A clinical trial to determine the efficacy of five years of Letrozole compared to placebo in patients completing five years of hormonal therapy consisting of an Aromatase Inhibitor (AI) or Tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with Hormone Receptor Positive Breast Cancer. |
ECOG E5103 |
A double-blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High-risk Lymph Node Negative Breast Cancer. |
IBCSG 25-02 |
A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (TEXT). |
B46 |
A Phase III Clinical Trial of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer |
GENITOURINARY |
|
RTOG 0621 |
Adjuvant 3DCRT/IMRT in Combination with Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II Trial |